Cited 0 times in
Efficacy of adjuvant gemcitabine-cisplatin chemotherapy: a comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, YS | - |
dc.contributor.author | Cho, JS | - |
dc.contributor.author | Cho, KS | - |
dc.contributor.author | Doo, SH | - |
dc.contributor.author | Chung, BH | - |
dc.contributor.author | Kim, SJ | - |
dc.contributor.author | Yang, WJ | - |
dc.contributor.author | Song, KH | - |
dc.contributor.author | Kim, CI | - |
dc.contributor.author | Hong, SJ | - |
dc.date.accessioned | 2011-06-09 | - |
dc.date.available | 2011-06-09 | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0042-1138 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/2866 | - |
dc.description.abstract | OBJECTIVE: To evaluate the comparative efficacy of adjuvant gemcitabine and cisplatin (GC) chemotherapy between patients with locally advanced transitional cell carcinoma (TCC) of the bladder and upper urinary tract.
PATIENTS AND METHODS: From 2001 to 2005, we retrospectively selected a total of 64 patients with locally advanced TCC of the bladder and upper urinary tract who received at least 3 cycles of adjuvant GC chemotherapy. We compared disease-free and overall survival between the 2 groups. RESULTS: The recurrence rate was 30.3% in TCC of the bladder and 25.8% of the upper urinary tract (p = 0.633). Statistical analysis revealed that there was no significant difference in the disease-free or overall survival rate between TCC of the bladder and upper urinary tract treated with adjuvant GC chemotherapy. CONCLUSION: Under the circumstances of limited data about TCC of the upper urinary tract, this study may suggest that adjuvant GC chemotherapy in locally advanced TCC of the upper urinary tract is as effective as those of bladder. | - |
dc.language.iso | en | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols | - |
dc.subject.MESH | Carcinoma, Transitional Cell | - |
dc.subject.MESH | Chemotherapy, Adjuvant | - |
dc.subject.MESH | Chi-Square Distribution | - |
dc.subject.MESH | Cisplatin | - |
dc.subject.MESH | Deoxycytidine | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Invasiveness | - |
dc.subject.MESH | Neoplasm Recurrence, Local | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Risk Assessment | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Urinary Bladder Neoplasms | - |
dc.subject.MESH | Urologic Neoplasms | - |
dc.title | Efficacy of adjuvant gemcitabine-cisplatin chemotherapy: a comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract. | - |
dc.type | Article | - |
dc.identifier.pmid | 20234122 | - |
dc.identifier.url | http://content.karger.com/produktedb/produkte.asp?DOI=000296294&typ=pdf | - |
dc.contributor.affiliatedAuthor | 김, 세중 | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1159/000296294 | - |
dc.citation.title | Urologia internationalis | - |
dc.citation.volume | 85 | - |
dc.citation.number | 1 | - |
dc.citation.date | 2010 | - |
dc.citation.startPage | 47 | - |
dc.citation.endPage | 51 | - |
dc.identifier.bibliographicCitation | Urologia internationalis, 85(1). : 47-51, 2010 | - |
dc.identifier.eissn | 1423-0399 | - |
dc.relation.journalid | J000421138 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.